Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy

ConclusionSpecial FDA designations shorten clinical development and FDA approval times for new drugs treating rare and severe diseases with unmet medical needs. Special-designated drugs offer a greater clinical benefit to patients. However, physicians, patients, and insurers must be aware that special-designated drugs are often approved based on non-robust trials, associated with more unrecognized side effects, and sold for higher prices.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research